Background β-Adrenergic agonists exert physiologic effects that are the opposite of those of
β-blockers. β-Blockers are known to reduce morbidity and mortality in patients with cardiac
disease. β 2-Agonist use in patients with obstructive airway disease has been associated
with an increased risk for myocardial infarction, congestive heart failure, cardiac arrest, and
acute cardiac death. Objectives To assess the cardiovascular safety of β 2-agonist use in
patients with obstructive airway disease, defined as asthma or COPD. Methods A meta …